메뉴 건너뛰기




Volumn 29, Issue 8, 2012, Pages 664-674

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; TNF blocker; Treatment gaps; Treatment patterns

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

EID: 84866478809     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0037-5     Document Type: Article
Times cited : (87)

References (24)
  • 3
    • 37349006854 scopus 로고    scopus 로고
    • The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review
    • DOI 10.1080/03009740701607067, PII 788637053
    • Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007;36:411-17. (Pubitemid 350293516)
    • (2007) Scandinavian Journal of Rheumatology , vol.36 , Issue.6 , pp. 411-417
    • Kristensen, L.E.1    Christensen, R.2    Bliddal, H.3    Geborek, P.4    Danneskiold-Samsoe, B.5    Saxne, T.6
  • 4
    • 72949116165 scopus 로고    scopus 로고
    • A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A cochrane overview
    • Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181:787-96.
    • (2009) CMAJ , vol.181 , pp. 787-796
    • Singh, J.A.1    Christensen, R.2    Wells, G.A.3
  • 5
    • 70350343375 scopus 로고    scopus 로고
    • Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis
    • Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209-18.
    • (2009) Dermatology , vol.219 , pp. 209-218
    • Bansback, N.1    Sizto, S.2    Sun, H.3    Feldman, S.4    Willian, M.K.5    Anis, A.6
  • 6
    • 49749120663 scopus 로고    scopus 로고
    • Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials
    • Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:513-26.
    • (2008) Br J Dermatol , vol.159 , pp. 513-526
    • Schmitt, J.1    Zhang, Z.2    Wozel, G.3    Meurer, M.4    Kirch, W.5
  • 7
    • 44349107161 scopus 로고    scopus 로고
    • Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials
    • Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90. (Pubitemid 351747132)
    • (2008) Journal of Rheumatology , vol.35 , Issue.5 , pp. 883-890
    • Saad, A.A.1    Symmons, D.P.M.2    Noyce, P.R.3    Ashcroft, D.M.4
  • 8
    • 36049048398 scopus 로고    scopus 로고
    • Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation
    • iii-iv
    • McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1-158, iii-iv.
    • (2007) Health Technol Assess , vol.11 , pp. 1-158
    • McLeod, C.1    Bagust, A.2    Boland, A.3
  • 9
    • 68149098843 scopus 로고    scopus 로고
    • Switching between tnfalpha antagonists in rheumatoid arthritis: Personal experience and review of the literature
    • Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 2009;61:107-17.
    • (2009) Reumatismo , vol.61 , pp. 107-117
    • Scrivo, R.1    Conti, F.2    Spinelli, F.R.3
  • 10
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a Large UK National Cohort Study
    • DOI 10.1002/art.22331
    • Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20. (Pubitemid 46106174)
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.1 , pp. 13-20
    • Hyrich, K.L.1    Lunt, M.2    Watson, K.D.3    Symmons, D.P.M.4    Silman, A.J.5
  • 11
    • 80052856528 scopus 로고    scopus 로고
    • Patterns of biologic agent utilization among patients with rheumatoid arthritis: A retrospective cohort study
    • Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.
    • (2011) BMC Musculoskelet Disord , vol.12 , pp. 204
    • Ogale, S.1    Hitraya, E.2    Henk, H.J.3
  • 12
    • 36749002002 scopus 로고    scopus 로고
    • Impact of concomitant dmard therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern sweden
    • Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.
    • (2006) Arthritis Res Ther , vol.8
    • Kristensen, L.E.1    Saxne, T.2    Nilsson, J.A.3    Geborek, P.4
  • 13
    • 50249107555 scopus 로고    scopus 로고
    • The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
    • Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229-34.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1229-1234
    • Kievit, W.1    Adang, E.M.2    Fransen, J.3
  • 14
    • 66249124273 scopus 로고    scopus 로고
    • Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
    • Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560-8.
    • (2009) Arthritis Rheum , vol.61 , pp. 560-568
    • Du Pan, S.M.1    Dehler, S.2    Ciurea, A.3    Ziswiler, H.R.4    Gabay, C.5    Finckh, A.6
  • 15
    • 70049109275 scopus 로고    scopus 로고
    • Tnf-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
    • Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-46.
    • (2009) Ann N Y Acad Sci , vol.1173 , pp. 837-846
    • Marchesoni, A.1    Zaccara, E.2    Gorla, R.3
  • 16
    • 62449314082 scopus 로고    scopus 로고
    • Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide
    • Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856-62.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1856-1862
    • Strangfeld, A.1    Hierse, F.2    Kekow, J.3
  • 17
    • 74849094402 scopus 로고    scopus 로고
    • Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide danish danbio registry
    • Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
    • (2010) Arthritis Rheum , vol.62 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3
  • 18
    • 84857233379 scopus 로고    scopus 로고
    • Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the spanish registry biobadaser 2.0
    • Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, Montoro M, Descalzo MA, Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012;71:382-5.
    • (2012) Ann Rheum Dis , vol.71 , pp. 382-385
    • Gomez-Reino, J.J.1    Rodriguez-Lozano, C.2    Campos-Fernandez, C.3    Montoro, M.4    Descalzo, M.A.5    Carmona, L.6
  • 19
    • 39449132386 scopus 로고    scopus 로고
    • The comparative one-year performance of anti-turmor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study
    • DOI 10.1002/art.23333
    • Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-40. (Pubitemid 351272960)
    • (2008) Arthritis Care and Research , vol.59 , Issue.2 , pp. 234-240
    • Heiberg, M.S.1    Koldingsnes, W.2    Mikkelsen, K.3    Rodevand, E.4    Kaufmann, C.5    Mowinckel, P.6    Kvien, T.K.7
  • 20
    • 34147219117 scopus 로고    scopus 로고
    • Survival of tnf antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the spanish registry biobadaser
    • Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.
    • (2006) Arthritis Res Ther , vol.8
    • Carmona, L.1    Gomez-Reino, J.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.